Clinical Trials
Advancing diversity in clinical trials requires joint efforts, novel strategies
Due to a complex interplay of genetic, lifestyle and environmental factors, as well as access to health care, the burden for advanced eye disease is highest among racial and ethnic minority groups.
First patient enrolled in phase 3 study of AZR-MD-001 for MGD
Azura Ophthalmics announced that the first patient has been enrolled in the phase 3 ASTRO study of AZR-MD-001 for patients with clinical signs and symptoms of meibomian gland dysfunction.
Race-neutral equations for COPD trial eligibility may lead to more Black patients enrolled
SAN DIEGO — Using race-neutral equations to determine eligibility for COPD clinical trials may lead to higher percentages of Black patients enrolled, according to a poster presented at the American Thoracic Society International Conference.
Positive phase 3 results reported in study of Guillain-Barre treatment
Annexon Biosciences has announced positive topline results from a phase 3, randomized placebo-controlled clinical trial examining an investigational monoclonal antibody in those with Guillain-Barré syndrome.
Positive results in phase 2b trial of orexin receptor agonist for narcolepsy type 1
Takeda has reported positive results from a phase 2b clinical trial of an investigational, oral orexin receptor agonist for narcolepsy type 1.
Clinical trials more accessible to rural areas, but barriers still persist
CHICAGO — More individuals with advanced cancers in the U.S. live within 30 miles of a clinical trial site than a decade ago, but those in rural areas, those with pancreatic disease and American Indians/Alaskan Natives still have access issues.
European Commission authorizes Qalsody for SOD1-ALS
The European Commission has granted marketing authorization under exceptional circumstances for Qalsody to treat those with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene.
FDA clears investigational new drug application for clinical trial of ALS pill
The FDA has cleared an investigational new drug application for a phase 1/2 clinical trial to examine a novel, once-daily pill for the treatment of individuals with amyotrophic lateral sclerosis, according to the manufacturer.
ASCO honoree uses unique vision to improve health equity, train emerging leaders
When Robert A. Winn, MD, learned he’d receive the Allen Lichter Visionary Leader Award at this year’s ASCO Annual Meeting, he reacted in the form of a question: “What just happened?”
VIDEO: Primary generalized tonic-clonic seizures pressing health issue for adolescents
DENVER — Primary generalized tonic-clonic seizures present unique challenges to adolescents diagnosed with the condition, Sunita Misra, MD, PhD, said in this Healio video at the American Academy of Neurology annual meeting.